Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Policy Commercial Financing

Attorneys Mull Takeaways From Conviction Of Theranos Founder Holmes

  • Analysis

Executive Summary

Elizabeth Holmes has been convicted on four counts of investor fraud. Two attorneys who followed the case spoke to Medtech Insight about what happened – and what it could mean for industry as a whole.

You may also be interested in...



Theranos' Holmes, Balwani Slammed By SEC For 'Massive Fraud'

In another blow from the US government, securities regulators have severely penalized Theranos and its cofounder, Elizabeth Holmes, for allegedly lying to investors to raise funds.

Industry And Investors Ponder Legacy Of Theranos Scandal

What lessons can be learned from the conviction of Theranos founder Elizabeth Holmes, found guilty on four counts of investor fraud in a US court on 4 January?

Warning Letter Close-Outs – December 2021

The US FDA released only one device-related close-out letter last month.

Table

View full table

Topics

Tags:
Policy Commercial Financing
UsernamePublicRestriction

Register

MT144914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By